Working… Menu

Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01097239
Recruitment Status : Withdrawn (Failure to recruit.)
First Posted : April 1, 2010
Last Update Posted : November 20, 2020
Imperial College Healthcare NHS Trust
Information provided by (Responsible Party):
Imperial College London

Brief Summary:

This is a single centre pilot trial to establish the feasibility and role of endoluminal HIFU in patients with locally advanced cancer within the pelvis that is either primary or recurrent and with all available current therapy inappropriate and/or exhausted.

The aim is to make a preliminary assessment of efficacy & dosage for evaluation in a randomised controlled trial. Whilst efficacy data are limited in a small feasibility study; radiological, biochemical and histopathological analysis of the patient and patient specimens, along with quality of life questionnaires (QoL), will be used to provide preliminary measures of efficacy in this patient cohort.

These analyses will allow examination of the biochemical, metabolomic and histological changes associated with HIFU treatment in cancer within the pelvis.

Condition or disease Intervention/treatment Phase
Rectal Cancer Ovarian Cancer Endometrial Cancer Vaginal Cancer Cervical Cancer Device: Sonablate 500 (High Intensity Focused Ultrasound (HIFU)) Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Phase I/II Feasibility/Efficacy Study of HIFU in Otherwise Untreatable Pelvic Rectal Cancer
Actual Study Start Date : November 2009
Actual Primary Completion Date : September 2018
Actual Study Completion Date : September 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ultrasound

Arm Intervention/treatment
Experimental: High Intensity Focused Ultrasound
Transrectal High Intensity Focused Ultrasound (HIFU) treatment of the PelvicTumour
Device: Sonablate 500 (High Intensity Focused Ultrasound (HIFU))
High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
Other Names:
  • Sonablate 500
  • HIFU

Primary Outcome Measures :
  1. Quality of life scores (EORTC QLQ-C30 and/or EORTC QLQ-CR38, EORTC QLQ-CX24, EORTC QLQ-EN24 or EORTC QLQ-OV24) [ Time Frame: Within the first 30, 60 and 90 days after HIFU ]
    Validated Quality of Life Questionnaire

Secondary Outcome Measures :
  1. Pain relief visual analogue scale [ Time Frame: Within the first 30, 60 and 90 days after HIFU ]
  2. Tumour marker changes (CEA and CA19.9) [ Time Frame: Within the first 30, 60 and 90 days after HIFU ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy proven rectal, vaginal, ovarian, endometrial or cervical cancer (tumour <15cm from anal/vaginal verge)
  • Lymph node(s) accessible by HIFU for which the primary clinical team advise intervention
  • Partially fixed/unresectable disease and locally advanced disease (T3/T4)
  • Patient considered to be unsuitable for or have exhausted all currently available therapies
  • WHO Performance Status 0-2
  • Fit for general anaesthetic and HIFU
  • Not pregnant
  • No other serious uncontrolled concomitant illness likely to interfere with treatment or assessment
  • Written informed consent for treatment

Exclusion Criteria:

  • WHO performance status of 3 or more
  • Uncontrolled cardiac, respiratory or other disease, or any serious medical or psychiatric disorder that would preclude anaesthetic or informed consent
  • Pelvic sepsis
  • Currently enrolled in any other treatment trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01097239

Layout table for location information
United Kingdom
Imperial College Healthcare NHS Trust (Hammersmith Hospital)
London, England, United Kingdom, W12 0HS
Sponsors and Collaborators
Imperial College London
Imperial College Healthcare NHS Trust
Layout table for investigator information
Principal Investigator: Paul D Abel, ChM FRCS(Lon) FRCS(Ed) Imperial College London
Study Chair: Leonardo Monzon, BSc MBBS MRCS(Eng) Imperial College Healthcare NHS Trust
Additional Information:

Layout table for additonal information
Responsible Party: Imperial College London Identifier: NCT01097239    
Other Study ID Numbers: 09/H0808/43
First Posted: April 1, 2010    Key Record Dates
Last Update Posted: November 20, 2020
Last Verified: November 2020
Keywords provided by Imperial College London:
High Intensity Focused Ultrasound
Rectal Cancer
Sonablate 500
Additional relevant MeSH terms:
Layout table for MeSH terms
Rectal Neoplasms
Endometrial Neoplasms
Vaginal Neoplasms
Neoplasms by Site
Genital Neoplasms, Female
Urogenital Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Uterine Neoplasms
Uterine Diseases
Vaginal Diseases